Caspase-8 has two opposing biological functions-it promotes cell death by triggering the extrinsic pathway of apoptosis, but also has a survival activity, as it is required for embryonic development 1 , T-lymphocyte activation 2 , and resistance to necrosis induced by tumour necrosis factor-a (TNF-a) and related family ligands 3, 4 .
Here we show that development of caspase-8-deficient mice is completely rescued by ablation of receptor interacting protein kinase-3 (RIPK3). Adult animals lacking both caspase-8 and RIPK3 display a progressive lymphoaccumulative disease resembling that seen with defects in CD95 or CD95-ligand (also known as FAS and FASLG, respectively), and resist the lethal effects of CD95 ligation in vivo. We have found that caspase-8 prevents RIPK3-dependent necrosis without inducing apoptosis by functioning in a proteolytically active complex with FLICE-like inhibitory protein long (FLIP L , also known as CFLAR), and this complex is required for the protective function.
The death receptor pathway of apoptosis is induced by ligation of a subset of tumour necrosis factor (TNF) receptor super-family members (the death receptors) 5 . This pathway involves the recruitment of an adaptor molecule, FADD, to the intracellular region of the receptor; FADD in turn binds and thereby activates caspase-8 to initiate apoptosis. Cell death in this pathway is antagonized by another protein, FLIP L (herein called FLIP), which resembles caspase-8 but lacks a catalytic site 5 .
Intriguingly, genetic ablation of caspase-8 (ref. 1), FADD 6 or FLIP 7 results in embryonic lethality around embryonic day E10.5, showing that these proteins function in cell survival as well as cell death. This is supported by the finding that caspase-8 deficiency by short interfering RNA (siRNA) knockdown or gene ablation sensitizes fibroblasts for necrotic cell death in response to TNF 3 (Supplementary Fig. 1a ). Necrosis induced by TNF in the presence of caspase inhibitors is dependent on the kinase activity of receptor-interacting protein kinase-1 (RIPK1) 4, 8 and RIPK3 (refs 9-11) , although the mechanisms remain obscure.
To determine if RIPK3-dependent necrosis contributes to the embryonic lethality of caspase-8-deficient mice, we generated Casp8 2/2 Ripk3 2/2 double knockout (DKO) animals. Although, as anticipated, we were unable to obtain viable Casp8 2/2 Ripk3 WT mice, Casp8 2/2 Ripk3 2/2 DKO mice were born at the expected frequency ( Fig. 1a ). These animals displayed no gross developmental abnormalities ( Supplementary Fig. 1b ), and their mass at different ages was indistinguishable from that of heterozygous mice ( Supplementary Fig. 1c ), as described for the Ripk3 2/2 mouse 12 , despite lacking detectable caspase-8 or RIPK3 ( Supplementary Fig. 1d ). Thymocytes from these animals underwent apoptosis in response to several agents known to induce the mitochondrial pathway of apoptosis, but were resistant to apoptosis induced by ligation of the death receptor CD95 ( Supplementary Fig. 1e ). We examined the latter effect in more detail, as injection of agonistic anti-CD95 antibody is known to trigger hepatocyte apoptosis, liver damage, and death in wild-type mice 13 . Whereas anti-CD95 caused liver destruction and mortality in heterozygous Casp8 1/2 Ripk3 2/2 animals, Casp8 2/2 Ripk3 2/2 mice were completely resistant to this insult ( Fig. 1b and Supplementary Fig. 1f -h).
In young Casp8 2/2 Ripk3 2/2 DKO mice, lymphoid organs appeared overtly normal ( Supplementary Fig. 2a ), T-lymphocyte proliferation in response to activation was identical to that of heterozygote littermates ( Supplementary Fig. 2b ), and T cells from these animals displayed expansion and subsequent peripheral deletion in vivo when challenged with the bacterial superantigen Staphylococcus enterotoxin B (SEB) ( Supplementary Fig. 2c ). However, we noted that older DKO mice displayed a striking lymphoaccumulation ( Fig. 2a ), resembling that described in animals lacking functional CD95 or CD95-ligand 14 . The latter are known to accumulate an unusual population of B220 1 , CD3 1 , CD4 2 , CD8 2 T lymphocytes, also seen in humans with defective CD95 or CD95-ligand 14 . Whereas young (1 month) Casp8 2/2 Ripk3 2/2 DKO mice showed normal mature T lymphocyte subsets, we observed a marked increase in B220 1 , CD3 1 cells as the animals aged ( Fig. 2b, Supplementary Fig. 2d ).
The ability of RIPK3 ablation to rescue the lethal phenotype of caspase-8 deletion strongly indicates that caspase-8-mediated inhibition of RIPK3-dependent necrosis is necessary for embryonic development, and that this is the primary protective role of caspase-8 in development. This raises the question of how caspase-8 can mediate this effect without itself engaging apoptotic cell death in the cells in which it manifests this protective function. A clue is provided by the observation that a mutant of caspase-8, lacking the cleavage site between the large and small subunits of the mature enzyme, rescued survival of caspase-8-deficient animals when expressed as a bacterial artificial chromosome (BAC)-transgene 15 . Such 'non-cleavable' caspase-8 has been shown to be unable to restore death-receptorinduced apoptosis in caspase-8-deficient cells 16, 17 . Biochemical and structural studies have indicated that FLIP can heterodimerize with caspase-8 in kosmotropic salt, and that this complex may be able to impart catalytic activity on caspase-8 in the absence of interdomain cleavage 18, 19 . We sought to test this directly by examining enzymatic activity of non-cleavable caspase-8 DA when dimerized with FLIP in vitro. We generated caspase-8 or non-cleavable caspase-8 DA , as well as FLIP, in which the prodomains were replaced by FKBP or FRB domains, respectively, allowing enforced homo-or heterodimerization upon addition of specific FK506 derivatives 20 . Although homodimerized FKBP-caspase-8 DA was catalytically inactive under physiological buffer conditions ( Supplementary Fig. 3a ) 16 , heterodimerization of this noncleavable caspase-8 with FRB-FLIP was enzymatically active (Fig. 3a) . Thus, FLIP can impart catalytic activity to non-cleavable caspase-8.
Because ablation of FLIP leads to developmental defects similar to those observed upon caspase-8 ablation 7 , and because expression of non-cleavable caspase-8 DA allows normal development, we proposed that FLIP may activate caspase-8 to allow suppression of RIPK3dependent death. To investigate this possibility, we generated mouse embryonic fibroblasts (MEF) from Casp8 2/2 Ripk3 2/2 DKO embryos and reconstituted them with caspase-8, non-cleavable caspase-8 DA or catalytically inactive caspase-8 CA , plus or minus RIPK3 (Fig. 3b ). We then knocked down FLIP expression by siRNA ( Supplementary Fig. 3b ). Cells lacking RIPK3 underwent cell death upon treatment with TNF only if they expressed wild-type caspase-8, and only if FLIP was lacking ( Fig. 3c ). Conversely, cells expressing RIPK3 died upon TNF exposure if they lacked caspase-8 or expressed catalytically inactive caspase-8 CA (Fig. 3d ). Importantly, cells expressing non-cleavable caspase-8 DA were resistant to TNF-induced, RIPK3-dependent death, but became sensitive to this form of cell death upon knockdown of FLIP ( Fig. 3d ). Thus, FLIP expression prevents caspase-8-dependent, RIPK3-independent death (apoptosis), and prevents RIPK3-dependent, necrotic cell death in a caspase-8-dependent manner. Apoptosis mediated by caspase-8 depends on cleavage of the caspase 16, 17 , whereas inhibition of RIPK3mediated cell death does not.
We obtained similar results in several cell lines. In murine SVEC cells, knockdown of caspase-8 or FLIP promoted TNF-induced cell 
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death, which in the case of caspase-8 was completely blocked by concomitant knockdown of RIPK3 (Fig. 3e, f and Supplementary Fig. 3c ). In contrast, TNF-induced cell death promoted by knockdown of FLIP was only partially dependent on RIPK3, presumably due to compensation by caspase-8-mediated apoptosis. This was supported by the combined knockdown of caspase-8 and FLIP, in which TNF-induced cell death was entirely RIPK3 dependent ( Fig. 3e, f) . Similar results were obtained in two 3T3 cell lines with (SA) or without (NIH) RIPK3 ( Supplementary Fig. 3d-f) .
In L929 cells, treatment with caspase inhibitor alone has been shown to cause RIPK3-dependent death due to autocrine production of TNF 16 . In these cells, knockdown of either caspase-8 or FLIP led to cell death that was fully dependent on RIPK3 ( Fig. 3g and Supplementary Fig. 3g ). For unknown reasons, no RIPK3-independent, caspase-8-dependent apoptosis was observed in these cells. However, together with the results obtained in Casp8 2/2 Ripk3 2/2 DKO MEF expressing non-cleavable caspase-8 DA (discussed above), these observations indicate that rather than simply functioning to dampen caspase-8 activation, FLIP is an important component of the protective effect.
CrmA is a pox-virus protein that potently inhibits the enzymatic activity of caspase-8 homodimers 21 (Fig. 4a) . Remarkably, the ability of CrmA to inhibit the activity of caspase-8 DA -FLIP heterodimers was strikingly attenuated (Fig. 4a ). Proposing that this property would allow discrimination between the cellular roles of caspase-8 homodimers and caspase-8-FLIP heterodimers, we expressed CrmA in RIPK3deficient 3T3-NIH cells or RIPK3-expressing 3T3-SA cells and examined the response to TNF (Fig. 4b) . CrmA blocked the RIPK3independent, caspase-8-dependent apoptotic death induced by TNF treatment of 3T3-NIH cells following FLIP knockdown. However, CrmA did not sensitize RIPK3-expressing 3T3-SA cells to TNFinduced death (Fig. 4b) , demonstrating that the inhibitor is not able to influence the 'survival' role of caspase-8. However, 3T3-SA cells expressing CrmA were readily sensitized to undergo TNF-dependent death by knockdown of caspase-8, FLIP, or both ( Fig. 4d ). Importantly, death induced by FLIP knockdown in 3T3-SA cells was only partially inhibited by the RIPK1 inhibitor necrostatin-1 (Nec1) or by stable knockdown of RIPK3, presumably due to contribution from caspase-8-dependent, RIPK3-independent apoptotic death under these conditions ( Fig. 4c and Supplementary Fig. 4a ). However, in CrmA-expressing 3T3-SA cells, the death induced by FLIP knockdown and TNF treatment was entirely inhibitable by Nec1 (Fig. 4d) , presumably due to CrmAmediated blockade of caspase-8-dependent apoptosis in these cells. These observations provide further support for the idea that the caspase-8-FLIP heterodimer is functionally active in inhibiting RIPK3dependent necrosis without promoting apoptosis.
We next sought to determine whether FLIP itself is required for the suppression of RIPK3-dependent TNF induced death, or whether it is merely required to dampen the apoptotic effect of caspase-8. To differentiate between these possibilities, we blocked the mitochondrial pathway of apoptosis in 3T3-SA cells by expression of the anti-apoptotic Bcl-2 family member Bcl-XL (also known as Bcl2l1), which blocks caspase-8-mediated apoptosis in many cells 22 . Strikingly, knockdown of FLIP in these cells strongly sensitized them to TNF-induced cell death, an effect that was completely inhibited by Nec1 or concomitant RIPK3 knockdown ( Fig. 4e and Supplementary Fig. 4b ). Western blot analysis showed appearance of fully-processed caspase-8 upon FLIP knockdown and TNF treatment in 3T3-SA cells with or without overexpression of Bcl-XL ( Supplementary Fig. 4c ). However, Bcl-XL expression blocked appearance of fully processed caspase-3 under these conditions, consistent with inhibition of the mitochondrial pathway of apoptosis ( Supplementary Fig. 4c ). Therefore, cells in which caspase-8 is activated but apoptosis is blocked nevertheless require FLIP for effective suppression of RIPK3-mediated death. Immunoprecipitation of FADD following TNF treatment of Bcl-XL expressing 3T3 cells did not coprecipitate RIPK1 or RIPK3 (Fig. 4f ). However, when caspase-8, FLIP, or both were knocked down in these cells, association of both RIPK1 and RIPK3 with FADD was observed ( Fig. 4f ). Cleaved caspase-8 was observed in whole lysates from these cells upon FLIP knockdown and TNF treatment, indicating that active caspase-8 was present in these cells, but was unable to prevent formation of the RIPK1-RIPK3 complex in the absence of FLIP ( Supplementary Fig. 4d ). Therefore, caspase-8-FLIP heterodimer, but not caspase-8 homodimer, prevents the stable association of FADD, RIPK1 and RIPK3, and prevents necrotic death.
The death of mice homozygous for caspase-8 deletion at E10.5 has been traced to a failure in early vascularization and haematopoietic development 1 . Our results demonstrate that this requisite role for caspase-8 in embryogenesis is eliminated by concurrent ablation of RIPK3. As RIPK3 is essential for programmed necrosis, the likely role of caspase-8 in development is to suppress the lethal effects of RIPK3, probably associated with necrotic death of endothelial and haematopoietic precursors. Consistent with this idea, we observed RIPK3 expression in haematopoietic tissues ( Supplementary Fig. 1d ). Further, we found that the ability of caspase-8 to inhibit RIPK3-dependent necrosis depends on the expression of FLIP. Caspase-8-FLIP heterodimers are enzymatically active, and this does not require cleavage of caspase-8 between its large and small subunits. In contrast, apoptosis induced by caspase-8 depends on such cleavage, which stabilizes the homodimer [15] [16] [17] 23 . This explains the ability of non-cleavable caspase-8 to rescue development in caspase-8-deficient mice without restoring sensitivity to death receptor-induced apoptosis 15 . This also explains the observation that activation of caspase-8-deficient T-cells causes cell death that is inhibitable by Nec1 24 . Our finding that T cells lacking both caspase-8 and RIPK3 proliferate normally is consistent with the idea that caspase-8 functions to suppress RIPK1-RIPK3-dependent LETTER RESEARCH cell death. Demonstration that non-cleavable caspase-8 can rescue T-cell proliferation 15 , along with our finding that FLIP can impart catalytic activity to this form of caspase-8, further supports an essential role for the caspase-8-FLIP complex in this process. Furthermore, because FLIP is a well known transcriptional target of NF-kB 25 , the suppression of RIPK3-dependent necrosis may represent a novel role for NF-kB signalling in immune cell proliferation. Taken together, these results support the idea that the main non-apoptotic function of caspase-8 is to suppress RIPK3-dependent necrosis during development and immune cell proliferation, and that it does so in complex with FLIP. Although caspase-8 may yet prove to have roles in other cellular processes, such as NF-kB activation 26 and cell motility 27 , our results do not provide support for such activities in development.
On the basis of the phenotypes of the caspase-8 (ref. 1), FADD 6 , and FLIP 7 -deficient animals, it is likely that the complex that protects cells from RIPK3-dependent necrosis includes all three of these components. Such complexes readily form in response to death receptor signalling 28 . At present, it is not known if development of caspase-8 deficient animals can be rescued by deletion of TNFR1, CD95, or the murine TRAIL receptor, all of which are capable of triggering RIPKdependent necrosis in the absence of caspase- 8 (ref. 4) . It is also possible that these (and their ligands) function redundantly to cause necrosis in caspase-8-deficient endothelium and haematopoietic cells, or that other death or immune receptors cause this effect.
The ability of CrmA to block caspase-8-mediated apoptosis but not the protective effect of caspase-8-FLIP indicates that some viruses can subvert this system to prevent both apoptosis and necrosis of infected cells. Consistent with our findings, T cells expressing a CrmA transgene were observed to resist death receptor-induced apoptosis, but unlike caspase-8-deficient T cells, showed no proliferative defects in response to activation 29 . In contrast, in one study CrmA overexpression was observed to sensitize L929 cells to TNF-induced necrosis; it is likely that in this case CrmA was expressed at high enough levels that its relatively weak inhibition of caspase-8-FLIP activity was sufficient to disrupt protection 3 .
The precise mechanism by which the catalytic activity of the caspase-8-FLIP complex is engaged to prevent RIPK3-dependent necrosis without triggering apoptosis is not presently known. Our data indicate that both caspase-8 and FLIP are required to disrupt formation of a stable complex containing FADD, RIPK1 and RIPK3 following TNF ligation. In cell-free systems, caspase-8-FLIP heterodimers display less proteolytic activity than caspase-8 homodimers on apoptotic substrates such as Bid and caspase-3 (refs 17, 30) . while maintaining a low but perceptible ability to cleave RIPK1 (ref. 30) . It is therefore possible that FADDdependent formation of caspase-8-FLIP heterodimers prevents stable RIPK1-RIPK3 association by cleaving RIPK1. However, the target and efficiency of this protease in vivo is likely to be determined by its recruitment to specific complexes, and the presence and availability of substrates therein, making it difficult to draw firm conclusions from biochemical studies. It remains possible that downstream targets of RIPK3 that cause necrosis (currently unknown) are the relevant substrates. NADPH-oxidase, mitochondrial reactive oxygen species production 3 , and metabolic enzymes 9 have been suggested to be possible downstream effectors of RIPK3, but at present, we do not know how these may be engaged by this kinase following its activation by RIPK1.
METHODS SUMMARY
Mice and treatments. Mice with a deleted allele of caspase-8 were generated by germ line deletion of a caspase-8 flox allele described previously 2 . RIPK3-deficient animals were obtained from V. Dixit 12 . Genotypes were confirmed by tail snip PCR as described previously. For Jo2 injections, animals were injected via tail vein with 15 mg purified Jo2 in lipopolysaccharide-free PBS per animal. Liver enzymes were assayed using a Trilogy Multi-Purpose Analyzer System from Drew Scientific, and liver sections were created and stained with haematoxylin and eosin, in the St. Jude Veterinary Pathology Core facility. For SEB injections, 50 mg SEB (Toxin Technology Inc.) per animal was injected via tail vein and T-cell populations were monitored by retro-orbital bleed and FACS as detailed previously. The St. Jude Institutional Animal Care and Use Committee approved all procedures in accordance with the Guide for the Care and Use of Animals.
METHODS siRNAs and DNA constructs. SiRNAs against caspase-8 (59-GUGAAUGGAAC CUGGUAUA-39 and 59-GUCACGGACUUCAGACAAA-39, catalogue number J-043044-05 and J-043044-06, respectively) and FLIP (59-GGAGCAAGAUC AAAUAUGA-39 and 59-GAAUAGACUUGAACACAAA-39, catalogue number J-041091-05 and J-041091-08 respectively) as well as scramble siRNA control (59-UGGUUUACAUGUCGACUAA-39, catalogue number D-001810-01) were ordered from Dharmacon, and introduced into cells using Lipofectamine RNAiMAX (Invitrogen) according to manufacturer's guidelines. Caspase-8 constructs were created by cloning full-length untagged murine caspase-8 upstream of a T2A ribosome-skipping sequence followed by green fluorescent protein (GFP), and introducing this construct into the pBabe-puro retroviral vector. The indicated D387A and C362A mutants were introduced using the QuikChange Mutagenesis kit from Agilent. For in cellulo experiments, CrmA was cloned into the pLNCX vector upstream of an IRES-GFP sequence, and cells transduced with this construct or vector control were sorted for GFP expression via FACS. Bcl-XLexpressing cell lines were produced by retroviral transduction of Bcl-XL-GFP fusion protein in pLZRS vector, followed by FACS sorting to achieve homogeneous expression. Cell lines. L929, SVEC 4-10 and 3T3-SA cell lines stably expressing scrambled or RIPK3-specific short hairpin RNAs were produced using the TRCN0000022535 lentiviral construct (hairpin sequence: 59-CCGGCCTCAGATTCCACATACTTT ACTCGAGTAAAG-TATGTGGAATCTGAGGTTTTT-39) from OpenBiosystems or control shRNA (59-CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGC GACTTAACCTTAGG-39) as previously described 31 . These cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% FCS, L-glutamine, and pen/strep. MEF were isolated from Casp8 2/2 Ripk3 2/2 embryos, transformed using E1A12S and H-RasG12V in pWZL-Hygro and pBabe-Puro retroviral vectors respectively, then selected in 0.5 mg ml 21 puromycin and 40 mg ml 21 hygromycin. These transformed cells were then transduced with the murine caspase-8 constructs described earlier, and sorted by FACS to achieve homogenous caspase-8 expression, then transduced with fulllength untagged murine RIPK3 in the pLZRS retroviral vector and selected in 100 mg ml 21 zeocin. MEF were maintained in DMEM as described above, but also supplemented with 55 mM b-mercaptoethanol, 1 mM sodium pyruvate and nonessential amino acids (Gibco). Caspase-8 flox/flox RosaCreER MEF were transformed as described above, and Cre recombinase was activated by culturing cells in 100 nM 4-hydroxytamoxifen for 48 h, followed by culture for 1 week to establish a stable population. Caspase-8 deletion was confirmed by PCR and western blot (not shown). Immunoprecipitation of FADD. 3T3-SA cells stably overexpressing Bcl-XL were transfected with siRNAs specific to FLIP, caspase-8, or with a scrambled control siRNA as described. 48 h post-transfection, cells were treated with 20 ng ml 21 recombinant murine TNF-a for 90 min. Immunoprecipitation of DISC-associated complexes was carried out using buffer and lysis conditions previously described 32 . FADD was immunoprecipitated using the M19 polyclonal anti-FADD antibody conjugated to Protein A/G-PLUS Agarose beads, also from Santa Cruz. Immune complexes were eluted by boiling in reducing western blot loading buffer and resolved by western blot using the antibodies described. Immune cell staining, cell death and activation assays. For immune cell staining, spleen, thymus and lymph node were harvested from animals and single cell suspensions were generated. For immune cells staining from the blood, blood was harvested weekly from the retrorbital sinus from animals anesthetized with 2-2.5% isoflurane in 1 l oxygen. Red blood cells were lysed in hypotonic buffer and samples were stained with the appropriate antibodies as described below. Data was acquired using a FACsCalibur or LSRII using CellQuest Pro and FACsDiva software, respectively. Data analysis was performed using FlowJo (Tree Star). For activation assays, splenic T cells were isolated from whole spleen using magnetic separation (Pan T cell isolation kit II, Miltenyi Biotec (130-095-130)). Cells were stained with CFSE and plated at 1 3 10 5 cells per well in 96-well plates with 10 mg ml 21 plate-bound anti-CD3 and 10 mg ml 21 soluble anti-CD28. For thymocyte death assays, single cell suspensions of thymocytes were plated at 1.5 3 10 5 cells per well in 96-well plates and treated with the various apoptosis inducers with or without 20 mM qVD. Cells were harvested at 8 h (or 22 h for Jo2), stained with AnnexinV and 7-AAD, and assayed for viability using flow cytometry. Splenocytes were cultured in RPMI 1640 (Invitrogen) supplemented as described for MEF above. Thymocytes were cultured in this media as well, but charcoal-stripped FBS was used. Compounds, antibodies and cytokines. Antibodies used for western blot were:
